A single-tube eight-color multiparametric flow cytometry (MFC) panel has good sensitivity for minimal/measurable residual disease (MRD) and excellent prediction for survival among patients with B-cell ...

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study Before HCT, 88 patients met morphologic criteria for complete remission (CR), ...

We evaluated all patients with a known or new diagnosis of SMM who were seen at the Mayo Clinic, Rochester from January 2008 until December 2013 and who had their peripheral blood evaluated for cPCs ...

SAN DIEGO--(BUSINESS WIRE)--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an ...

SAN DIEGO--(BUSINESS WIRE)--Today Invivoscribe, a global leader in precision diagnostics, announced the launch of a new 12-color multiparametric flow cytometry service in Shanghai, China, the newest ...

The last decade has seen a revolution in cancer immunotherapy. The demand from doctors, researchers, and pharmaceutical companies for more precise results with high sensitivity and high-quality ...

Flow cytometry remains a critical technology for the high-throughput analysis of single cells in complex populations. Attention to good analysis practices is more important than ever due to the recent ...

Although flow cytometry was invented more than 45 years ago, it continues to grow and expand into new areas that marry it with other modern cutting-edge technologies. Harnessing the power of the full ...

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial Invivoscribe Inc., a ...